PTPN22 and myeloid sarcoma: Significant changes also occurred in the ES to MS stage with a reduction in PLCH2 (p = 2.19 × 10−16), DAGL (p = 0.0004), GDE7 (p = 0.0009) and an increase in PLCB2 (p = 0.002) and PTPN22 (p = 0.001).